Natalia Nowak

Dr. Natalia Nowak

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in Kidney International
Verified
Journal Article
Closed access
PDF file
NNNatalia Nowak
Natalia Nowak
JSJan Skupien
Jan Skupien
MNMonika A. Niewczas
Monika A. Niewczas
MYMasayuki Yamanouchi
Masayuki Yamanouchi
MMMelissa Major
Melissa Major
AKAndrzej S. Krolewski
Andrzej S. Krolewski

1 May 2018 in Kidney International
Verified
Journal Article
Closed access
NNNatalia Nowak
Natalia Nowak
JSJan Skupien
Jan Skupien
ASAdam M. Smiles
Adam M. Smiles
MYMasayuki Yamanouchi
Masayuki Yamanouchi
MNMonika A. Niewczas
Monika A. Niewczas
AKAndrzej S. Krolewski
Andrzej S. Krolewski

4 August 2011 in Diabetologia
Verified
Journal Article
Closed access
PDF file
GTG. Thanabalasingham
G. Thanabalasingham
NSN. Shah
N. Shah
MVM. Vaxillaire
M. Vaxillaire
THT. Hansen
T. Hansen
TTT. Tuomi
T. Tuomi
KOK. R. Owen
K. R. Owen

2 February 2013 in Diabetologia
Verified
Journal Article
Open access
PDF file
NNNatalia Nowak
Natalia Nowak
JSJ. Skupien
J. Skupien
KCK. Cyganek
K. Cyganek
BMB. Matejko
B. Matejko
MMMaciej Malecki
Maciej Malecki
Aims/hypothesis Most pregnant women with type 1 diabetes mellitus achieve HbA1c targets; however, macrosomia remains prevalent and better pregnancy glycaemic markers are therefore needed. 1,5-Anhydroglucitol (1,5-AG) is a short-term marker of glycaemia, reflecting a period of 1 to 2 weeks. Its excretion rate depends on the renal glucose threshold and thus it is unclear whether it may be used in pregnant type 1 diabetes women. We evaluated 1,5-AG as a glycaemic marker and birthweight predictor in pregnant women with type 1 diabetes, and compared its performance with HbA1c. Methods 1,5-AG and HbA1c were measured in 82 pregnant women with type 1 diabetes. In addition, 58 continuous glucose monitoring system (CGMS) records were available. Macrosomia was defined as birthweight >90th centile. The data were analysed with Pearson’s correlations, and linear and logistic regression models. Receiver operating characteristic (ROC) analysis was used to evaluate third trimester 1,5-AG as a predictor of macrosomia. Results Unlike HbA1c, 1,5-AG strongly correlated with CGMS indices: the AUC above 7.8 mmol/l (r = −0.66; p < 0.001), average maximum glucose (r = −0.58; p < 0.001) and mean glucose (r = −0.54; p < 0.001). In the third trimester, 1,5-AG was the strongest predictor of macrosomia, with ROC AUC 0.81 (95% CI 0.70, 0.89). In contrast, HbA1c in the third trimester had a ROC AUC of 0.69 (95% CI 0.58, 0.81). The best discrimination was achieved when both markers were used jointly, yielding a ROC AUC of 0.84 (95% CI 0.76, 0.93). Conclusions/interpretation In pregnant women with type 1 diabetes, 1,5-AG is a better glycaemic marker than HbA1c, as assessed by CGMS. A decreased third trimester 1,5-AG level, either singly or with HbA1c, is a strong predictor of macrosomia.

15 November 2012 in Diabetic Medicine
Verified
Journal Article
Open access
PDF file
SMS. A. Mughal
S. A. Mughal
RPR. Park
R. Park
NNNatalia Nowak
Natalia Nowak
AGAnna Gloyn
Anna Gloyn
FKF. Karpe
F. Karpe
KOK. R. Owen
K. R. Owen
Aims: Missed diagnosis of maturity‐onset diabetes of the young (MODY) has led to an interest in biomarkers that enable efficient prioritization of patients for definitive molecular testing. Apolipoprotein M (apoM) was suggested as a biomarker for hepatocyte nuclear factor 1 alpha (HNF1A)‐MODY because of its reduced expression in Hnf1a–/– mice. However, subsequent human studies examining apoM as a biomarker have yielded conflicting results. We aimed to evaluate apoM as a biomarker for HNF1A‐MODY using a highly specific and sensitive ELISA.Methods: ApoM concentration was measured in subjects with HNF1A‐MODY (n = 69), Type 1 diabetes (n = 50), Type 2 diabetes (n = 120) and healthy control subjects (n = 100). The discriminative accuracy of apoM and of the apoM/HDL ratio for diabetes aetiology was evaluated.Results: Mean (standard deviation) serum apoM concentration (μmol/l) was significantly lower for subjects with HNF1A‐MODY [0.86 (0.29)], than for those with Type 1 diabetes [1.37 (0.26), P = 3.1 × 10–18) and control subjects [1.34 (0.22), P = 7.2 × 10–19). There was no significant difference in apoM concentration between subjects with HNF1A‐MODY and Type 2 diabetes [0.89 (0.28), P = 0.13]. The C‐statistic measure of discriminative accuracy for apoM was 0.91 for HNF1A‐MODY vs. Type 1 diabetes, indicating high discriminative accuracy. The apoM/HDL ratio was significantly lower in HNF1A‐MODY than other study groups. However, this ratio did not perform well in discriminating HNF1A‐MODY from either Type 1 diabetes (C‐statistic = 0.79) or Type 2 diabetes (C‐statistic = 0.68).Conclusions: We confirm an earlier report that serum apoM levels are lower in HNF1A‐MODY than in controls. Serum apoM provides good discrimination between HNF1A‐MODY and Type 1 diabetes and warrants further investigation for clinical utility in diabetes diagnostics.

1 April 2010 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
BKBarbara Katra
Barbara Katra
TKTomasz Klupa
Tomasz Klupa
JSJan Skupien
Jan Skupien
MSMagdalena Szopa
Magdalena Szopa
NNNatalia Nowak
Natalia Nowak
MMMaciej T. Malecki
Maciej T. Malecki
Background: In HNF1A maturity-onset diabetes of the young (MODY), sulfonylurea (SU) is the first-line treatment. Over time, such therapy fails, and additional treatment is required. Dipeptidyl peptidase IV (DPP-IV) inhibitors are new agents that lower blood glucose by prolonging the activity of circulating incretins. Methods: We applied DPP-IV inhibitors in two HNF1A MODY patients whose earlier therapeutic regimen included SU. Results: Case 1, a 39-year-old woman, a carrier of the ArgR171X HNF1A mutation, with a 7-year history of diabetes was on 160 mg of gliclazide and 2,000 mg of metformin. Her initial hemoglobin A1c (HbA1c) level was 7.2%, while the mean glucose level on the CGMS ® (Medtronic, Northridge, CA) record was 162 mg/dL. Sitagliptine, in a dose of 100 mg/day, was added to the previous treatment. Case 2, a 62-year-old woman, a carrier of the IVS7nt-6G>A mutation, with a 41-year history of diabetes was treated with 240 mg/day gliclazide and 6 IU of insulin/day. Her initial HbA1c was 8.8%, and average glycemia reached 172 mg/dL. In her case, we started the combined therapy with 50 mg of vildagliptine twice daily. Patients were reexamined after 3 months, and HbA1c fell to 6.3% in both subjects. Similarly, significant improvement in glycemic control on CGMS was observed as the average glycemia decreased to 114 mg/dL and 134 mg/dL in Case 1 and Case 2, respectively. No episodes of hypoglycemia or other side effects were recorded. As intravenous glucose tolerance tests (IVGTTs) were performed before and after DPP-IV implementation, we were able to assess their impact on insulin secretion under fasting conditions. We saw a substantial rise in insulin level increment during IVGTT (by 9.8 and13.4 mIU/L in Case 1 and Case 2, respectively). Conclusions: DPP-IV inhibitors may be an effective tool of combined therapy in HNF1A MODY, and they seem to improve beta-cell function under fasting conditions.